In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Track this case

Case overview

Case Number:

2:17-md-02785

Court:

Kansas

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Daniel D. Crabtree

Firms

Companies

Sectors & Industries:

  1. August 20, 2018

    Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL

    Mylan NV and Pfizer Inc. on Monday largely failed to scale down multidistrict litigation over sky-high prices for emergency allergy treatment EpiPen, as a Kansas federal judge mostly refused to throw out wide-ranging consumer claims of anti-competitive shenanigans.

  2. June 12, 2018

    Humana Ordered To Turn Over Docs In EpiPen Antitrust MDL

    A Kansas federal judge on Monday ordered Humana Inc. to hand over within three weeks documents related to a multidistrict litigation accusing drugmaker Mylan NV of antitrust violations related to a surge in the price of its allergy treatment device, the EpiPen.